Bayer AG reported a 3% increase in group sales to EUR24 billion for the first half of 2026, with core earnings per share up 3% to EUR3.66. The CropScience division delivered 5.5% sales growth and expanded its EBITDA margin to 31%, while Pharma's new products Nubeqa and Karendia combined for 66% growth, offsetting declines in Xarelto and Eylea. Free cash flow was negative EUR2.7 billion, driven by EUR2.5 billion in litigation-related payouts, and net financial debt stood at EUR33.6 billion, expected to fall to EUR29-30 billion following a EUR3 billion equity investment from Apollo. CEO Bill Anderson highlighted a landmark U.S. Supreme Court ruling in Monsanto v. Durnell as a victory providing regulatory clarity and strengthening the company's litigation containment strategy.
Bayer AG NAReports sales growth, EPS increase, and landmark litigation victory
Apollo Global Management LLC Class AApollo makes EUR3 billion equity investment in Bayer